T20K

T20K is a synthetic peptide drug candidate in development for the treatment of multiple sclerosis (MS), a chronic autoimmune disease affecting the central nervous system. It is being developed as a first-in-class therapy with prophylactic properties, aiming to mitigate or prevent MS episodes and potentially delay or halt disease progression. T20K acts by reversibly targeting interleukin-2 (IL-2), an important cytokine involved in immune regulation and implicated in the breakdown of myelin, which is characteristic of MS pathology[5]. Preclinical studies have shown that T20K can reduce inflammation and has a favorable safety profile with low toxicity. The drug has completed phase I clinical trials demonstrating good safety and tolerability in healthy volunteers, with no serious adverse events reported[2][7]. Cyxone is developing both intravenous and oral formulations of T20K, aiming for convenient administration at low doses on a bi-weekly or monthly basis[1][3].